StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
MEDN.TA$33400.00+0.66%
Fair $33400.00+0.0%

MEDN.TA

Mehadrin Ltd

Consumer Defensive / Farm ProductsTel Aviv

$33400.00

+220.00 (+0.66%)

Fairly Valued+0.0%Fair Value $33400.00Fund rank 24/100 · Data gapFallback financials|
SA 50/C
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $-11.3M · quality 37.0/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 16/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

50/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · MEDN.TALocal privado en este navegador · Mehadrin Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.1B

P/E

8.8x

↓

EV/EBITDA

603.2x

↑

ROE

19.8%

↑

Gross Margin

5.3%

↓

Debt/Equity

0.75

↑
52-Week Range$33400
$187$33890

TradingView lightweight chart

MEDN.TA price, volumen y niveles de valoración

Último $33,470Periodo +46711.2%
Fair value: $33,400

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+2.8%

FCF CAGR

—

FCF margin

3.4%

FCF / Net income

0.29x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.11B · net income $130.3M · FCF $38.1M

2022-FY → 2025-FY

Gross margin

5.3%+13.6% pts

Operating margin

1.7%+12.9% pts

Net margin

11.7%+20.3% pts

FCF margin

3.4%+7.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.11B$1.11B$965.3M$1.13B$1.02B
Net Income$130.3M$130.3M$-73.9M$-154.8M$-87.1M
EBITDA$191.1M$191.1M$-16.4M$-105.0M$-40.5M
EPS——-22.80-46.56-25.97
Gross Margin5.3%5.3%-2.3%-1.0%-8.3%
Operating Margin1.7%1.7%-6.2%-3.7%-11.2%
Net Margin11.7%11.7%-7.7%-13.7%-8.5%
Balance Sheet
Debt/Equity0.750.750.830.750.70
Current Ratio2.112.11———
Cash Flow
Free Cash Flow$38.1M$38.1M$-11.3M$-12.0M$-43.5M
Returns
ROE19.8%19.8%-14.4%-26.7%-14.2%
Valuation
P/E8.798.79———
EV/EBITDA603.24603.24———
P/B174.29174.291.150.910.68
Growth & Yield
Revenue Growth15.0%15.0%-14.8%11.0%—
EPS Growth——51.0%-79.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +17741.2%

Total return

+17741.2%

Start / end P/E

n/dx → n/dx

EPS bridge

-22.80 → n/d

Residual

+17741.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+17741.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.